Abstract
While direct oral anticoagulants (DOACs) have been proven effective in stroke prevention in patients with non-valvular AF (NVAF), there is limited evidence-based guidance on DOAC use in valvular atrial fibrillation. This scoping review aims to examine clinical cerebrovascular outcomes and safety profiles within valvular AF (VAF) patients treated with DOACs. This scoping review was conducted following the Joanna Briggs Institute methodology for scoping reviews and reported consulting the Preferred Reporting Items for Systematic Review and Meta-Analysis extension for scoping reviews checklist. Pubmed, OVID Medline and Web of Science databases were searched for manuscripts published from inception to July 25, 2022 and included based on pre-registered criteria. Data extraction included patient demographics, valvular disease and Afib classification, DOAC type, cerebro-cardiovascular outcomes variables, and bleeding risks. There were 12 studies with 69,741 VAF patients treated with DOACs. At the 12-month follow-up, acute ischemic stroke and major bleeding events occurred in 3.5% and 5.8% of these patients, respectively. DOACs in VAF were associated with similar clinical cerebrovascular outcomes with decreased risk of fatal bleeding rates when compared to warfarin. More controlled studies are needed to further assess the safety and efficacy of DOACs in this population.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work received no funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data can be requested through the authors.
